Onyx reported total revenue of $362.2 million for the full year 2012 and $127.9 million for the fourth quarter 2012. Onyx reported non-GAAP net loss of $162.9 million, or $2.50 per diluted share, for ...
SOUTH SAN FRANCISCO, CA--(Marketwire - Nov 1, 2012) - Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the third quarter 2012. Onyx reported non-GAAP net loss of ...
With an all-important FDA decision on carfilzomib scheduled for July 27, Onyx hopes to graduate to the next stage of commercial success. For a feature-length profile of Onyx and CEO Tony Coles ...
Approved in July of 2012 as Onyx's first wholly-owned product, Kyprolis, serves as the foundation for our proprietary proteasome inhibitor franchise. We've executed a successful launch in the United ...
Onyx Pharmaceuticals, Inc. ONXX today reviewed 2012 accomplishments and announced several 2013 business updates, which the company discussed during its presentation at the 31st Annual J.P. Morgan ...
SOUTH SAN FRANCISCO, CA -- November 1, 2012 -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the third quarter 2012. Onyx reported non-GAAP net loss of $51.8 ...
SOUTH SAN FRANCISCO, CA--(Marketwire - Nov 1, 2012) - In the news release "Onyx Pharmaceuticals Reports Third Quarter 2012 Financial Results," issued earlier today by Onyx Pharmaceuticals (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results